Androgen deprivation therapy remains to be the mainstay of treatment for advanced prostate cancers. Recent clinical studies showed that treatment with degarelix leads to improved disease control in comparison to an LHRH agonist with regards to excellent PSA progression-free success, recommending that degarelix most likely delays development to castration-resistant disease and includes a even more… Continue reading Androgen deprivation therapy remains to be the mainstay of treatment for